Papadopoulou Lefkothea
Najam (Naj) Sharif, PhD, DSc, FARVO, FBPhS, FAOPT
Vice President and Head

Global Alliances & External Research (GAER)
Ophthalmology Innovation Center
Santen Inc. (USA), California, USA
Phone: +1 (415) 268-9181



2019 Awarded DSc Degree (thesis) University of Southampton (England, UK)
2018- Present Vice President, Therapeutic Area Head Global Alliances & External Research (Santen Inc., California, USA)
2014-2017 Executive Director, Head Biomedical Sciences/ Alliances & External Research (Santen Inc. California, USA)
2004-2014 Director (Pre-clinical Pharmacology, Imaging & Biomedical Engineering; and Global Regulatory Affairs Manager) Alcon-Novartis (Fort Worth, Texas, USA)
1999-2004 Director (Preclinical Glaucoma & Retinal Research) Alcon Laboratories (Fort Worth, Texas, USA)
1992-1999 Associate Director (Ophthalmology Discovery Research) Alcon Laboratories (Fort Worth, Texas, USA)
1991-1992 Group Leader (Neuroscience Discovery Research) Synaptic Pharma / Lundbeck (Paramus, NJ, USA)
1988-1991 Staff Researcher I-II (Neuroscience Discovery Research) Syntex Pharmaceuticals (Palo Alto, USA)
1985-1988 Staff Scientist (Neuroscience Discovery Research) Parke-Davis / Pfizer (Cambridge, UK)
1982-1985 Postdoctoral Fellowships University of Maryland (Baltimore, USA) & Nottingham University (UK)
1978-1982 PhD (Neuropharmacology) (Southampton University, England, UK); Cooperative Award in Science & Engineering Grant from UK Research Council & Imperial Chemical Industries (ICI; AstraZeneca)
1975-1978 BSc (Physiology & Biochemistry (Joint Honors)) Southampton University, England, UK



Najam Sharif, PhD, DSc has >34-years pharmaceutical drug discovery research/development experience covering neuroscience and ophthalmology. His 22-year tenure at Alcon resulted in his contributions to the discovery, characterization, development and US FDA approvals of Patanol®/Pataday®/Pazeo® and Emadine® to treat allergic conjunctivitis, and Travatan® and Simbrinza® for the treatment of ocular hypertension / Glaucoma. Currently, he is vice president, Global Alliances and External Research, Ophthalmology Innovation Center at Santen Inc. USA, where he has been instrumental in establishing, nurturing and managing long term partnerships with pharma companies and several global universities. Dr. Sharif serves on numerous committees of many learned Societies (including ISER, elected Trustee of AOPT & Gold Fellow; Gold Fellow of ARVO and Fellow of British Pharmacological Society (BPS)). Dr. Sharif is Editor/Associate Editor/Editorial Board member of many Pharmacology and Ophthalmic journals. He is the recipient of the inaugural Dr. Roger Vogel award for ocular pharmaceutical research (ARVO Foundation, 2104), the recipient of the “Sir James Black Award” for contributions to drug discovery (BPS, 2017), and awarded of the Ernst Barany Prize for outstanding contributions to ocular pharmacology. Dr. Sharif is an Adjunct Professor / Honorary Senior Lecturer / Senior Principal Investigator and graduate Faculty at multiple Universities worldwide. He has also been a PhD-candidates’ supervisor, advisor and mentor to several students at numerous academic institutions. Dr. Sharif has published >215 scientific articles, edited 3 books, holds 24 issued US/EU patents, and has filed >30 patent applications over the last two decades.

Research Interest

Research Expertise

  1. High Through-Put Screening: Conducted and familiar with Receptor Binding Assays for >30 different receptors and their sub-types. For example: amino acids; TRH; muscarinic drugs; α- & β-adrenoceptors; 5HT1A, 5HT1B, 5HT1D, 5HT2A-C, 5HT3; 5HT4, 5HT5, 5HT6, 5HT7; DP/EP/FP/IP/TP prostaglandins, opioid peptides; angiotensin II; bradykinin; CCK; histamine1-4., PAF, corticosteroids. -- Utilized Biomek Robotics Systems & Activity Base for data-analysis / data-mining from HTS platforms.
  2. Second Messenger & Other Functional Assays: e.g. Phosphoinositide/Inositol Phosphate Extraction and analysis by TLC and ion exchange chromatography for defining agonist/antagonist action of neurotransmitters and drugs. FLIPR-based, real-time intracellular Ca2+ mobilization assays. Fluorescence polarization assays for kinases; Cell Impedance Assays; ELISA and EIA Assays. HTRF assays for IP1/ cAMP.
  3. Molecular Biology: Familiar with receptor cloning, expression and use of recombinant proteins in drug discovery. Familiar with & the use of RT-PCR / RNAase protection procedures to study receptor mRNAs in cells / tissues to complement target verification / localization to support drug discovery.
  4. Autoradiographic Techniques: serotonin; opioids; Prostaglandins; TRH; CCK; angiotensin II; bradykinin; muscarinics; endothelin; NPY; NGF; prostaglandins, adrenoceptors, etc. Target Localization & Verification.
  5. Computerized Image Analysis for quantification of receptor autoradiograms (established the Quantimet 970 image analysis system at the PDRU in Cambridge and at Syntex Research, USA; Cyclone Phosphor-imager/ Optiquant at Alcon).
  6. In Situ Hybridization: Receptor & Peptide mRNAs using oligonucleotides; (e.g. Bradykinin; c-fos; NGF-1A, etc) for Target Localization & Verification.
  7. Neurotransmitter Uptake & Release mechanisms, and Stereotactic Lesioning Techniques for functional in vitro/ in vivo studies.
  8. Tissue / cell Culture Techniques for growing homogeneous cells in monolayers (established a culture suite at PDRU in Cambridge, UK).
  9. Design and supervision of in vivo experiments, including behavioral studies and in vivo ocular studies (at Syntex/Roche and at Alcon).
  10. Ocular Imaging Overseeing use of various techniques and technologies (e.g. fluorotron angiography; OCT; Immunohistochemistry).
  11. Other Disciplines/ Functions: Managed and directed several large teams composed of senior researchers/ managers engaged in discovery/development research employing techniques and technologies in Formulations/CMC, Pharmacokinetics (PK), Pharmacodynamics (PD), Drug Metabolism/ Toxicology, Pharmacology (in vitro/in vivo), Regulatory Affairs, Marketing, Intellectual Property (IP), etc.


Scientific Activities:

Teaching Experience
2020- Present Appointed Adjunct Professor by Duke-National University of Singapore (Duke-NUS) Medical School, Singapore
2020-Present Taught part of “Advanced Pharmacology- PH 809” classes (“Receptors as Pharmaceutical Drug Targets”)- (Spring semester) (Pharmaceutical Sciences, Department of Pharmacology, Texas Southern University, Houston, Texas, USA)
2018-2019 Taught part of “Neuropharmacology- PH 912” classes (Fall semester) (Pharmaceutical Sciences, Department of Pharmacology, Texas Southern University, Houston, Texas, USA)
2018-Present Appointed Adjunct Senior Principal Investigator at SERI (Singapore)
2018-Present Appointed Adjunct Clinical Professor, Creighton University School of Pharmacy (Omaha, NE)
2017-Present Appointed Honorary Senior Lecturer (Imperial College London, UK)
2016-2017 Taught part of “Neuropharmacology- PH 912” classes (Fall semester) (Pharmaceutical Sciences, Texas Southern University, Houston, Texas, USA)
2015-Present PhD Thesis Advisor (Department of Pharmacology, Texas Southern University, Houston, Texas, USA)
2010-Present Adjunct Professor, Pharmaceutical Sciences, Department of Pharmacology (Texas Southern University, Houston, Texas, USA)
2010-2014 PhD Thesis Advisor (Texas Southern University, Houston, Texas, USA)
2008-2009 Corporate Advisory Board member at University of Houston School of Pharmacy (Houston, Texas, USA)
2005-2008 Adjunct Professor, School of Pharmacy (University of Houston, Houston, Texas, USA)
1999-2000 Adjunct Professor & Graduate Faculty at Creighton University School of Pharmacy (Omaha, NE); MS Thesis Advisor (Creighton University School of Pharmacy, Omaha, NE)
1994-1997 PhD Supervisor (Alcon employee, who conducted research at UNTHSC and at Alcon in my Labs)
1994-Present Adjunct Professor and Graduate Faculty at University of North Texas Health Science Center (UNTHSC) (Fort Worth, Texas, USA)
1991-1992 Wrote and submitted an RO1-NIMH research grant on “Heterogeneity of Motilin Receptors and drug discovery” (Synaptic Pharma Corp., Paramus, NJ)
1988-1991 Hosted, mentored and taught six University of California undergraduate interns [Neuropharmacology research] at Syntex Research (Palo Alto, CA)
1983-1984 Taught “Molecular Pharmacology” to Medical Students (University of Maryland, Baltimore, USA)
1979-1981 Tutor in Pharmacology for MSc-level students (Southampton University, UK)

Honors & Awards

  1. Recipient of a Co-operative Award in Science & Engineering (CASE) Project for PhD graduate work, supported by ICI /Zeneca; (Alderley Park, Macclesfield, UK) and Science & Engineering Council of UK. (1978-1981).
  2. Awarded competitive Traveling Fellowship by the Weizman Institute of Science (Israel) to participate in a special by-invitation-only (150 scientist’s total) workshop on “Neurotransmitters & Their Receptors,” Rehovot & Tel-Aviv (Israel), Feb. 1980 during graduate student PhD research.
  3. Member of the Alcon Corporate Patents Committee. A select team of 15 senior managers from Alcon across the world (many based at Alcon HQs in TX). (2005-2010).
  4. Joint Steering Committee (JRC) member of Collaboration Technical Team (one of three senior scientific /management Alcon members) during a multi-year collaboration with Chiroscience / Celltech (Cambridge, UK) & Albany Molecular (Bothel, WA) (2005-2008).
  5. 5. Corporate Advisory Board (CAB) member at University of Houston, School of Pharmacy (2008-2009).
  6. Elected to Assoc. for Research in Vision & Ophthalmology (ARVO) Diversity Initiative Committee (served during 2009-2012).
  7. Bio-graphed in “Marquis Who’s Who in Medicine & Healthcare”, 2011-2012 (8th Edition).
  8. Elected to ARVO’s Annual Meeting Program Committee (AMPC) for Physiology/Pharmacology section to serve for three years (2012-2015).
  9. Awarded the 1st and inaugural “Dr. Roger Vogel Award” for Pharmaceutical Research (awarded at ARVO, May 2014).
  10. Elected as Fellow of ARVO (FARVO) and presented the Silver Medal (May, 2015).
  11. Elected to serve on the “Commercial Relations Committee [CRC]” of ARVO (Serving 2016-2019).
  12. Santen Board member (Observer) on InnFocus Inc. (device company) (Miami, FL) Board of Directors (2016).
  13. Elected as Fellow of British Pharmacological / Pharmaceutical Society (BPS) (FBPhS, 2016).
  14. Appointed as Head of Joint Research Committee of multi-year Santen-SERI Research Collaboration (March, 2016).
  15. Appointed Honorary Senior Lecturer at Imperial College London (London, UK) (2017).
  16. Awarded the “Sir James Black Award” for “Contributions to Drug Discovery” (BPS; Dec. 2017).
  17. Appointed as Adjunct Clinical Professor, Pharmacy Sciences Department, School of Pharmacy & Health Professions, Creighton University, Omaha, NE (Jan. 2018- June 2021).
  18. Appointed as Adjunct Senior Principal Investigator at Singapore Eye Research Institute (SERI), Singapore (2018-2020).
  19. Elected “Gold Fellow” of ARVO Society (January 2019).
  20. Elected to ISER Committee for Commercial Relations/ Fund raising (2019).
  21. Elected as Trustee of Assoc. Ocular Pharmacology & Therapeutics (AOPT) (March 2019).
  22. Awarded Doctor of Science (DSc by thesis) degree by Southampton University (UK) (June 2019).
  23. Elected to the Board of Directors of The Glaucoma Foundation (TGF), Manhattan, NY City, NY (Jan 2020).
  24. Elected “Fellow of Assoc. Ocular Pharmacol. Therapeutics”, (FAOPT), (March 2020).
  25. Appointed as Adjunct Professor, Duke-NUS Medical School, Singapore (June 2020).
  26. Awarded the Ernst H Barany prize for “outstanding contributions to ocular pharmacology” by ISER (Nov. 2020).
  27. Elected to the Scientific Advisory Board of The Glaucoma Foundation (May 2021).
  28. Received Innovation Award for Inflammasome Inhibitor program from Santen Ophthalmology Innovation Center Leadership Committee (June 2021).

Granted/Issued Patents & Published Patent Applications

  1. Use of NR2B-selective NMDA-receptor antagonists for treatment of ophthalmic diseases. Issued: US 6291479 (Sharif; Sept 2001).
  2. Immortalized human corneal epithelial cell-line. Issued: US 6284537 (Offord-Cavin, Pfeifer, Sharif, Tromvoukis; Sept 2001).
  3. Prostaglandin E agonists for treatment of dry eye. Issued: US 6344477 (Sharif; Feb 2002).
  4. 11β-fluoro-15β-hydroxy-PGF2α analogs as FP receptor antagonists. Issued: US 6441033 (Sharif & Griffin; August 2002).
  5. Non-peptide bradykinin antagonists for use in controlling intraocular pressure and treating glaucoma. Issued: US 6500831 (Sharif; Dec 2002).
  6. Treatment of FP receptor activation-related disorders, e.g. ocular hyperemia, involves use of 11-deoxy-16-fluoro-PGF2α analogs. Issued: US 6492417 (Sharif & Griffin; Dec 2002).
  7. Non-peptide bradykinin antagonists for use in treating ophthalmic diseases and disorders. Issued: US 6531480 (Sharif; March 2003).
  8. Prostaglandin E agonists for treatment of glaucoma. Issued: US 6545045 (Klimko, Sharif, Griffin; April 2003).
  9. 11-deoxy-16-fluoro-PGF2α and 11β-fluoro-15β -hydroxy-PGF2α analogs as FP receptor antagonists. Issued: US 6649655 (Sharif & Griffin; Nov 2003).
  10. 11β-fluoro-15β-hydroxy-PGF2α analogs as FP receptor antagonists. Issued: US 6649655 (Sharif, Griffin; 2003).
  11. Serotonergic 5HT2 agonists for treating glaucoma. Issued: US 6664286 (May, Dean, Sharif, Hellberg; Dec 2003).
  12. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders. Issued: US 7060704 (May, Dean, Sharif, Chen; June 2006).
  13. Lignee immortalisee de cellules epitheliales humaines de la cornee (Immortalized human corneal epithelial cell-line). Issued: EP 0851028 (Offord-Cavin, Tromvoukis, Pfeifer, Sharif; Dec 2006).
  14. Methods of treating dry eye disorders. Issued: US 7235556 (Sharif, Hellberg; June 2007).
  15. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders. Issued: US 7285553 (May, Dean, Sharif, Chen; October 2007).
  16. (Indazol-5-yl)-pyrazines and (1,3-hihydro-indol-2-one)-pyrazines for treating glaucoma and controlling intraocular pressure. Issued: US 7655662 (Hellberg, Sharif, May, Rusinko, Chen; 2010).
  17. Methods for treating glaucoma comprising administering α-lipoic acid. Issued: US 7718697 (Drace, Williams, Kelly, Sharif; May 2010).
  18. Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucoma. Issued: US 7807629 (Sharif; October 2010).
  19. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions. Issued: US 7867999 (Chen, Sharif, Hellberg; Jan 2011).
  20. Use of non-peptidic bradykinin receptor agonists to treat ocular hypertension and glaucoma. Issued: US 8173668 (Sharif; May 2012).
  21. Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma. Issued: US 8252793 (Combrink, Mohapatra, Hellberg, Sharif, Prasanna, et al.; August 2012).
  22. Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucoma. Issued: US 8263555 (Sharif; Sept 2012).
  23. Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension. Issued: US 9604949 B2 (Ellis, Scheibler, Sharif; March 2017).
  24. Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension. Issued: US 10016441 (Ellis, Scheibler, Sharif; July 2018).
  25. The use of 5HT1b/1d drugs for treating ocular pain. Published: WO 1997/44062 (Gamache, Sharif; Nov 1997).
  26. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders. Published: WO 1999 / 59499-A2. (May, Dean, Sharif, Chen; Nov 1999).
  27. Muscarinic agents and uses thereof to treat glaucoma, myopia and various other conditions. Published: WO 1999 / 32481 (Namil, Hoffman, Hellberg, Dean, Feng, Chen, Sharif, Dantanaryana; 1999).
  28. The use of 5HT1b/1d agonists to treat otic pain. Published: WO 2001/15677 (Sharif, Gamache, Yanni; 2001).
  29. Use of implanted encapsulated cells expressing glutamate transporter proteins for the treatment of neurodegenerative diseases. Published: US 2001/ 0041174-A1 (Sharif; 2001).
  30. Ophthalmological compositions containing serotonin 5HT1A receptor agonists and their use in the treatment of glaucoma. Published: WO 1998/18458 A1 (DeSantis, Osborne, Sharif, Sallee; May 1998).
  31. Substituted 5-hydroxy-indole compounds for the treatment of glaucoma. Published: WO 2003/051291- A3 (Namil, Sharif, Zinke, Dean; 2003).
  32. Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus, and improving body balance. Published: US 2005/ 222127 A1 (Sharif; October, 2005).
  33. Use of agents that prevent generation of amyloid, amyloid-like lipoproteins, and/or use of agents that promote sequestration and/or degradation of, and/or prevent neurotoxicity of such proteins in the treatment of hearing loss and improving body balance. Published: US 2005/ 137122 A1 (Sharif; June 2005).
  34. Use of agents that down-regulate expression of tanis and/or p21Waf1/Cip1/Sd1 genes, and use of agents that inhibit, degrade, sequester or prevent the neurotoxicity of gene product proteins of tanis and p21Waf1/Cip1/Sd1 genes. Published: US 2005 / 137123 A1 (Drace, Williams, Kelly & Sharif; June 2005).
  35. Use of agents that prevent the generation of amyloid-like proteins and/or drusen, and/or use of agents that promote sequestration and/or degradation of, and/or prevent the neurotoxic effects of such proteins in the treatment of macular degeneration. Published: US 2006 / 121039 A1 (Sharif, Drace & Williams; June 2006).
  36. Use of natriuretic peptide receptor antagonists to treat ocular, otic and nasal edematous conditions. Published: US 2007 / 0225225 A1 (Sharif, Katoli; Sept 2007).
  37. Antagonists of C1-M6P/ IGF2R for prevention and treatment of CTGF-mediated ocular disorders. Published: US 2008/ 0057072 A1 (Shepard, Fleenor, Clark, Sharif; March 2008).
  38. High-throughput assay for human Rho kinase activity with enhanced signal-to-noise ratio. Published: US 2008 / 0096238 A1 (Sharif, Drace, Williams; April 2008).
  39. RNAi-mediated inhibition of aquaporin-1 for treatment of IOP-related conditions. Published: US 2008/ 20080171719 A1 (Chatterton, Patil, Sharif, Clark, Wax; July 2008).
  40. RNAi-mediated inhibition of aquaporin-4 for treatment of ocular neovascularization. Published: US 2008/ 0194513 A1 (Patil, Chatterton, Sharif, Wax; August 2008).
  41. RNAi-mediated inhibition of aquaporin-4 for treatment of IOP-related conditions. Published: US 2008/ 0214486 A1 (Chatterton, Patil, Sharif, Clark, Wax; September 2008).
  42. RNAi-mediated inhibition of aquaporin-1 for treatment of ocular neovascularization. Published: US 2009/ 0054365 A1 (Patil, Chatterton, Sharif, Wax; February 2009).
  43. Use of multi-pharmacophore compounds to treat nasal disorders. Published: US 2011/ 0195962 A1 (Sharif, Wax; August 2011).
  44. Prophylactic and/or therapeutic agent containing pyridyl amino-acetic acid compound. (Kirihara, Shimizaki, Sharif, 2015). (Japanese Patent; submitted); PCT Filed 7th July 2016.
  45. Prophylactic and/or therapeutic agent containing pyridyl amino-acetic acid compound. Published: US 2018/ 0200239 A1 (Kirihara, Shimazaki, Sharif, July 2018).



  1. Roberts PJ, Sharif NA. Effects of L-glutamate and related amino acids upon the release of [3H]-dopamine from rat striatal slices. Brain Research 157: 391-394 (1978). (paper resulting from an under-graduate research project)
  2. Sharif NA, Roberts PJ. Problems associated with binding of L-glutamic acid to synaptic membranes - methodological aspects. Journal of Neurochemistry 34: 779-784 (1980).
  3. Sharif NA, Roberts PJ. Effects of protein and membrane modifying agents on the binding of [3H]-glutamate to cerebellar membranes. Brain Research 194: 594-597 (1980).
  4. Sharif NA, Roberts PJ. Effects of guanine nucleotides on binding of [3H]-glutamate to cerebellar synaptic membranes. European J. Pharmacology 61: 213-214 (1980).
  5. Sharif NA, Roberts PJ. Cerebellar glutamate receptors: Studies on their stability, susceptibility to protein and membrane modifying agents and effects of guanine nucleotides. In: Neurotransmitters and Their Receptors. UZ Litauer et al. (eds). John Wiley & Sons, London, pp. 369-372 (1980).
  6. Sharif NA, Roberts PJ. L-aspartate binding sites in rat cerebellum: comparison of [3H]-aspartate and [3H]-glutamate binding to synaptic membranes. Brain Research, 211, 293-303 (1981).
  7. Roberts PJ, McBean GJ, Sharif NA, Thomas, EM. Striatal glutamatergic function: modification following specific lesions. Brain Research 235: 83-91 (1981).
  8. Sharif NA, Roberts PJ. Regulation of cerebellar [3H]-glutamate binding: influence of guanine nucleotides and Na+ ions. Biochemical Pharmacology 30: 3019-3022 (1981).
  9. Roberts PJ, Sharif NA. Radioreceptor binding studies with glutamate and aspartate. In: Glutamate as a Neurotransmitter. Vol. 27, Advances in Biochemical Pharmacology, G. di Chiara & GL. Gessa (eds), Raven Press, NY, pp. 298-305 (1981).
  10. Roberts PJ, Foster GA, Sharif NA, Collins JF. Phosphonate analogs of acidic amino acids: inhibition of excitatory amino acid binding to cerebellar membranes and of the stimulation of cerebellar cyclic GMP levels. Brain Research 238: 475-479 (1982).
  11. Sharif NA, Burt DR, Towle AC, Mueller RA, Breese GR. Codepletion of serotonin and TRH induces apparent supersensitivity of spinal TRH receptors. European J. Pharmacology 95: 301-304 (1983).
  12. Sharif NA, Zuhowski EG, Burt DR. Benzodiazepines inhibit TRH receptor binding - micromolar potency in retina, amygdala and pituitary. Neuroscience Letters 41: 301-306 (1983).
  13. Sharif NA, Burt DR. Rat brain TRH receptors: kinetics, pharmacology, distribution and ionic effects. Regulatory Peptides 7: 399-411 (1983).
  14. Sharif NA, Burt DR. Receptors for thyrotropin-releasing hormone (TRH) in the rabbit spinal cord. Brain Research 270: 259-263 (1983).
  15. Sharif NA., Burt DR. Micromolar substance P reduces spinal TRH receptor binding-possible relevance to neuropeptide coexistence? Neuroscience Letters., 43, 245-251 (1983).
  16. Sharif NA, Burt DR. Biochemical similarity of rat pituitary and CNS TRH receptors. Neurosci. Letts 39: 57-63 (1983).
  17. Sharif NA, Pilotte, NS, Burt DR. Biochemical and autoradiographic studies of TRH receptors in sections of rabbit spinal cord. Biochemical Biophysical Research Communications 116: 669-674 (1983).
  18. Pilotte N, Sharif NA, Burt DR. Characterization and autoradiographic localization of TRH receptors in sections of rat brain. Brain Research 293: 372-376 (1984).
  19. Sharif NA, Burt DR. Sulphydryl groups in receptor binding of thyrotropin releasing hormone to rat amygdala. Journal of Neurochemistry 42: 209-214 (1984).
  20. Sharif NA. Apparent super high-affinity recognition sites in rat cortical membranes: allosteric sites for peptides? IRCS. Medical Science, 12, 1038-1039 (1984).
  21. Sharif NA, Burt DR. Modulation of receptors for thyrotropin releasing hormone by benzodiazepines: brain regional differences. Journal of Neurochemistry 43: 742-746 (1984).
  22. Sharif NA, Roberts PJ. Neurochemical, pharmacological and developmental studies on cerebellar receptors for dicarboxylic amino acids. Neurochemical Research, 9, 81-102 (1984).
  23. Sharif NA. Motor neuron disease- a role for TRH. Trends in Pharmacological Sciences. 5(3): 88-89 (1984).
  24. Sharif NA. Excitatory Amino Acid Receptors. In: Handbook of Neurochemistry, Vol. 6, (A. Lajtha, Ed), Chapter 9, pp.239-250, Plenum Press, New York (1984).
  25. Sharif NA. Comparative autoradiographic visualization of muscarinic, benzodiazepine and TRH receptors in mammalian spinal cord slices. IRCS. Medical Science 12: 1016-1017 (1984).
  26. Burt DR, Sharif NA. Peptide Receptors. In: Handbook of Neurochemistry, Vol. 6 (A. Lajtha, Ed), Chapter 13, pp. 353-378, Plenum Press, New York (1984).
  27. Sharif NA. Serotonin1 (5HT1) receptors modulate striatal dopaminergic transmission: studies on uptake, release and receptor mechanisms. IRCS Medical Sciences 13: 368-369 (1985).
  28. Sharif NA. Diverse roles of thyrotropin-releasing hormone in brain, pituitary and spinal cord function. Trends Pharmacological Sciences 6: 119-122 (1985).
  29. Sharif NA, Burt DR. Limbic, hypothalamic, cortical and spinal regions are enriched in receptors for TRH: evidence from [3H]-Ultrofilm autoradiography and correlation with central effects of the tripeptide in rat brain. Neuroscience Letters 60: 337-342 (1985).
  30. Sharif NA, Burt DR. Visualization and identification of TRH receptors in rodent brain by autoradiography and radioreceptor assays: focus on amygdala, n. accumbens, septum and cortex. Neurochemistry International 7: 525-532 (1985).
  31. Sharif NA. Multiple synaptic receptors for neuroactive amino acid transmitters-new vistas. International Reviews in Neurobiology 26: 85-150 (1985).
  32. Sharif NA. Support for analeptic action of thyroliberin (TRH) - apparent induction of limbic forebrain TRH receptors after ethanol treatment. IRCS Medical Sciences 13: 60-61 (1985).
  33. Sharif NA. Review of Book entitled “Measurement of Neurotransmitter Release In Vivo”, Edited by CA Marsden, John Wiley (1984). Trends Pharmacological Sciences 6: 418-419 (1985).
  34. Sharif NA. Meeting Report for conference entitled “Brain Imaging: new approaches to neuronal Communication”. Trends Pharmacological Sciences 7: 46-47 (1986).
  35. Sharif NA. Adaptive changes in brain and pituitary TRH receptors: effects of lesions, kindling, hormones, drugs and other factors. Medical Science Research 15: 223-227 (1987).
  36. Sharif NA, Burt DR. Guanine nucleotide regulation of receptors for TRH in rat brain regions and pituitary. Neuroscience Letters 81: 339-344 (1987).
  37. Sharif NA, White WF, Burt DR. Properties & distribution of TRH receptors in normal & spastic mutant mouse brain & spinal cord. Neurochemistry International 11: 63-68 (1987).
  38. Sharif NA. Effects of some peptidase inhibitors on TRH-receptor interactions in rat amygdala homogenates. Medical Science Research 16: 219-220 (1988).
  39. Sharif NA, Whiting RL. [125I]ω-conotoxin labels picomolar spinal and brain N-type Ca2+-channels: modulation by cations and endothelin. Medical Science Research 16: 1183-1184 (1988).
  40. Clark CR, Birchmore B, Sharif NA, Hunter JC, Hill RG, Horwell D, Hughes J. PD117302: a new kappa-selective opioid agonist. British J. Pharmacology 93: 618-626 (1988).
  41. Sharif NA. Chronic prolactin, gonadal and thyroid hormone treatments in vivo alter levels of TRH and muscarinic receptors in male and female rat tissues. Brain Research 449: 364-368 (1988).
  42. Sharif NA, Hunter JC, Hill RG, Hughes, J. Bradykinin-induced accumulation of [3H]inositol-1-phosphate in human embryonic pituitary tumor cells by activation of a B2-receptor. Neuroscience Letters 86: 279-283 (1988).
  43. Sharif NA, Michel AD, Whiting RL. Affinities of bradykinin analogs and identification of B2 bradykinin receptors in guinea pig brain, spinal cord and peripheral tissues using [3H]-BK binding. Medical Science Research 16: 1235-1236 (1988).
  44. Tones M, Sharif NA, Hawthorne JN. Phospholipid turnover during cell-cycle traverse in synchronous Chinese-Hamster ovary cells. Biochemical Journal 249: 51-56 (1988).
  45. Sharif NA, Hunter JC, Hill RG, Hughes, J. [125I]-dynorphin (1-8) produces a similar pattern of kappa opioid receptor labelling to [3H]-dynorphin (1-8) and [3H]-etorphine in guinea pig brain: a quantitative autoradiographic study. Neuroscience Letters 86: 272-278 (1988).
  46. Sharif NA. Chemical and surgical lesions of the rat olfactory bulb: changes in thyrotropin-releasing hormone and other systems. Journal of Neurochemistry 50: 388-394 (1988).
  47. Sharif NA. Quantitative autoradiography of TRH receptors in discrete brain regions of different mammalian species. Annals New York Academy of Sciences 553: 147-175 (1989).
  48. Sharif NA, Michel AD, Whiting RL. Human endothelin stimulates phosphoinositide turnover in murine fibrosarcoma cells. Medical Science Research 17: 55-56 (1989).
  49. Sharif NA, Hughes J. Discrete mapping of brain mu and delta opioid receptors using selective peptides: quantitative autoradiography, species differences and comparison with kappa receptors. Peptides 10: 499-522 (1989).
  50. Eglen RM, Michel AD, Sharif NA, Swank S, Whiting RL. Pharmacological properties of the peptide, endothelin. British J. Pharmacology 97: 1297-1307 (1989).
  51. Sharif NA, Michel AD, Whiting RL. [3H]-U69593 and [3H]-etorphine binding suggests the absence of multiple kappa opioid receptors in dog cerebral cortex. Medical Science Research 17: 213-214 (1989).
  52. Sharif NA, Hughes J. Neuroanatomical mapping and quantification of peptide and drug receptors by quantitative digital subtraction autoradiography. In: Brain Imaging: Techniques and Applications. (Sharif NA, Lewis ME; Eds). Ellis Horwood Ltd, Chichester, pp. 36-76 (1989).
  53. Sharif NA, Nunes JL, Michel AD, Whiting RL. Comparative properties of the dopamine transport complex in dog and rodent brain: striatal [3H]-GBR12935 binding and [3H]dopamine uptake. Neurochemistry International 15: 325-332 (1989).
  54. Sharif NA, To Z, Michel, AD, Whiting, RL. Differential affinities of TRH analogs at the mammalian spinal cord TRH receptor: implications for therapy in spinal injuries. Neuroscience Letters 104: 183-188 (1989).
  55. Sharif NA, Towle AC, Burt DR, Mueller RA, Breese GR. Co-transmitters: differential effects of serotonin (5HT)-depleting drugs on 5HT and TRH levels and their receptors in rat brain and spinal cord. Brain Research 480: 365-371 (1989).
  56. Sharif NA, To Z, Whiting RL. First pharmacological characterization of TRH receptors linked to phosphoinositide hydrolysis in GH3 pituitary cells using agonist specificity of eight TRH analogs. Biochemical Biophysical Research Communications 161: 1306-1311 (1989).
  57. Sharif NA. A novel substance P binding site in rat brain regions modulates TRH receptor binding. Neurochemical Research 15: 1045-1049 (1990).
  58. Burt DR, Sharif NA. TRH receptors. In: Handbook of Chemical Neuroanatomy. (Bjorklund A, Hökfelt T, Kuhar MJ, Eds), Academic Press, Chapter 9, Vol. 9, pp. 477-503, (1990).
  59. Sharif NA, Whiting RL. Stimulation of inositol phosphate production in clonal HSDM1C1 cells by endothelins and sarafotoxin. Biochemical Pharmacology 40: 1928-1931 (1990).
  60. Sharif NA, Whiting RL. Identification of B2-bradykinin receptors in guinea pig brain regions, spinal cord and peripheral tissues. Neurochemistry International 18: 89-96 (1991).
  61. Sharif NA, Durie E, Michel AD, Whiting RL. Dog cerebral cortex contains μ-, δ- and κ-opioid receptors at different densities: lack of evidence for sub-types of κ-receptor using selective radioligands. Brain Research 510: 108-114 (1990).
  62. Nunes JL, Sharif NA, Michel AD, Whiting RL. Dopamine D2-receptors mediate hypothermia in mice: icv and ip effects of agonists and antagonists. Neurochemical Research 16: 1167-1174 (1991).
  63. Sharif NA, Wong EH, Loury D, Stefanich E, Eglen RM, Michel A, Whiting RL. Characteristics of 5HT3 binding sites in rat cerebral cortex, NG108-15 and NCB-20 neuroblastoma cells using [3H]-quipazine and [3H]-GR65630 binding. British J. Pharmacology 102: 919-925 (1991).
  64. Sharif NA, To ZP, Whiting RL. Analogs of thyrotropin-releasing hormone (TRH): receptor affinities in brains, spinal cords and pituitaries of different species. Neurochemical Research 16: 95-103 (1991).
  65. Ransom J, Cherwinski HM, Dunne JF, Sharif NA. Flow cytometric analysis of internal calcium mobilization via a B2-bradykinin receptor in a subclone of PC12 cells. Journal of Neurochemistry 56: 983-989 (1991).
  66. Ransom J, Cherwinski HM, Delmendo R, Sharif NA, Eglen R. Characterization of m4 muscarinic receptor Ca2+ responses in a subclone of PC-12 cells by single cell flow cytometry. Journal Biological Chemistry 266: 11738-11745 (1991).
  67. Sharif NA, Nunes JL, Whiting RL. Pharmacological characterization of NMDA-receptor-channel in rodent and dog brain and rat spinal cord using [3H]MK-801 binding. Neurochemical Research 16: 563-569 (1991).
  68. Sharif NA, Nunes JL, Kalfayan V, McLelland DL, Rosenkranz RP, Eglen RM, Whiting RL. Pharmacological comparison of [3H]-GBR12935 binding to rodent striatal and kidney homogenates: binding to dopamine transporters? Neurochemistry International 21: 69-73 (1992).
  69. Ransom JT, Sharif NA, Dunne J, Momiyama M, Melching G. AT-1 angiotensin receptors mobilize intracellular calcium in a subclone of NG108-15 neuroblastoma cells. Journal of Neurochemistry 58: 1883-1888 (1992).
  70. Sharif NA. TRH Analogs and Receptors. In: Methods in Neuroscience, Chapter 13, Vol. 13, pp.199-219 (Conn PM, Ed.), Academic Press (1993).
  71. Sharif NA, Stevenson DJ. Chinese hamster ovary (CHO-K1) cells: optimum culture conditions, cell-cycle events and phospholipid metabolism- response to serum and calcium ionophore A23187. Medical Science Research 21: 553-556 (1993).
  72. Kubek MJ, Knoblach SM, Sharif NA, Burt DR, Butterbaugh GG, Fuson KS. TRH gene expression and receptors are differentially modified in limbic foci by seizures. Annals of Neurology 33: 70-76 (1993).
  73. Sharif NA, Whiting RL. The neuropeptide bradykinin stimulates phosphoinositide turnover in HSDM1C1 cells: B2-antagonist-sensitive responses and receptor binding studies. Neurochemical Research 12: 1313-1320 (1993).
  74. Sharif NA, Eglen RM. Quantitative Autoradiography: A Tool to Visualize and Quantify receptors, Enzymes, Channels and Second Messenger Systems. In: Molecular Imaging in Neuroscience: A Practical Approach, (Sharif NA, Ed.), pp. 71-138, Oxford University Press (1993).
  75. Eglen RM, Sharif NA, To ZP. Muscarinic M3 receptors mediate total inositol phosphates accumulation in murine HSDM1C1 fibrosarcoma cells. European J. Pharmacology (Mol. Pharmacol.) 244: 49-55 (1993).
  76. Ransom JR, Dunne JF, Sharif NA. Flow Cytometric selection of responsive subclones and fluorimetric analysis of intracellular calcium mobilization. In: Molecular Imaging in Neuroscience: A Practical Approach. (N.A.Sharif, Ed.), pp.209-233, Oxford University Press (1993).
  77. Sharif NA, Xu S, Yanni JM. Emedastine (Emedine®): a potent, high affinity histamine H1-selective antagonist for ocular use. Receptor binding and second messenger studies. Journal Ocular Pharmacology 10: 653-664 (1994).
  78. Sharif NA, Xu S, Yanni JM. Histamine receptor-subtype affinities, selectivities and potencies of emedastine (Emedine®), a novel H1-selective antagonist, and other ocularly employed antihistamines. Drug Development Research 33: 448-453 (1994).
  79. Sharif NA, To ZP, Wong KW, Delmendo RE, Whiting RL, Eglen RM. M3 muscarinic receptors on murine HSDM1C1 cells: further functional, regulatory and receptor binding studies. Neurochemical Research 20: 61-68 (1995).
  80. Sharif NA, Williams GW, DeSantis LM. Affinities of muscarinic drugs for [3H]N-methylscopolamine (NMS) and [3H]-Oxotremorine (OXO) binding to a mixture of M1-M4 muscarinic receptors: Use of NMS/OXO ratios to group compounds into potential agonist, partial agonist and antagonist classes. Neurochemical Research 20: 669-674 (1995).
  81. Sharif NA, Nunes JL, Lake KD, Rosenkranz RP, McClelland,DL, Corkins,S, Lakatos,I, Whiting, RL, Eglen,RM. Chronic manipulation of dietary salt modulates renal physiology and kidney dopamine receptors: functional and autoradiographic studies. General Pharmacology 26: 727-735 (1995).
  82. Chidlow G, DeSantis LM, Sharif NA, Osborne NN. The characteristics of [3H]5-hydroxytrytamine binding to iris-ciliary body of the rabbit. Investigative Ophthalmology & Visual Science 36: 2238-2245 (1995).
  83. Sharif NA, Nunes JL, Rosenkranz, RP, Eglen, RM, Whiting, RL. Quantitative autoradiography demonstrates selective modulation of brain regional dopamine (D1 & D2) receptor subtypes after chronic manipulation of dietary salt. Neurochemical Research 20: 121-128 (1995).
  84. Blue D, Bonhaus D, Ford APD, Pfister J, Sharif NA, Shieh A, Vimont R, Williams T, Clarke DE. Functional evidence equating the pharmacologically-defined α1A- and cloned α1C-adrenoceptors: studies in the isolated perfused kidney of rat. British J. Pharmacology 115: 283-294 (1995).
  85. Sharif NA. Quantitative Autoradiographic Methods. In: Brain Mapping - The Methods. (A.Toga & J. Mazziotta, Eds.), Chapter 5, pp. 115-144, Academic Press, New York (1996).
  86. Sharif NA Xu S, Magnino P, Pang I-H. Human conjunctival epithelial cells express histamine-1 receptors coupled to phosphoinositide turnover and intracellular calcium mobilization: role in ocular allergic & inflammatory diseases. Experimental Eye Research 63: 169-178 (1996).
  87. Sharif NA, Xu S, Yanni JM. Olopatadine (AL-4943A; Patanol®): Ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist for use in allergic conjunctivitis. Journal Ocular Pharmacology & Therapeutics 12: 401-407 (1996).
  88. Sharif NA, Xu SX. Pharmacological characterization of bradykinin receptors coupled to phosphoinositide turnover in SV40-immortalized human trabecular meshwork cells. Experimental Eye Research 63: 631-637 (1996).
  89. Sharif NA, Xu SX, Miller ST, Gamache DA, Yanni JM. Characterization of the ocular anti-allergic and anti-histaminic effects of Olopatadine (AL-4943A; Patanol®), a novel drug for treating ocular allergic diseases. J. Pharmacology & Experimental Therapeutics 278: 1251-1260 (1996).
  90. Crider JY, Williams GW, Yorio T, Sharif NA, Griffin BW. A new chromatographic method for rubidium transport activities in cultured bovine retinal pigmented epithelial cells. Ophthalmic Research 29: 117-123 (1997).
  91. Crider JY, Yorio T, Sharif NA, Griffin, BW. The effects of elevated glucose on Na+/K+-ATPase of cultured bovine retinal pigment epithelial cells measured by a new nonradioactive rubidium uptake assay. Journal Ocular Pharmacology & Therapeutics 13: 337-352 (1997).
  92. BenEzra D, Griffin BW, Maftzir G, Sharif NA, Clark AF. Topical formulations of novel angiostatic steroids (AL-3789; Anecortave acetate) inhibit rabbit corneal neovascularization. Investigative Ophthalmology & Visual Science 38: 1954-1962 (1997).
  93. Sharif NA, Hellberg MH, Yanni JM. Anti-histamines, topical ocular. In: Burger's Medicinal Chemistry & Drug Discovery, 5th edition, (Wolff MF, ed.), John Wiley & Sons, NY, Chapter 64, Volume 5, pp. 255-279 (1997).
  94. Wiernas TK, Griffin BW, Sharif NA. The expression of functionally-coupled bradykinin receptors in human corneal epithelial cells and their pharmacological characterization with agonists and antagonists. British J. Pharmacology 121: 649-656 (1997).
  95. Sharif NA, Crider JY, Griffin B, Howe W, Davis T. Pharmacological analysis of mast cell mediator and neurotransmitter receptors coupled to adenylate cyclase and phospholipase C on immunocytochemically-defined human conjunctival epithelial cells. J. Ocular Pharmacology & Therapeutics 13: 321-336 (1997).
  96. Griffin BW, Williams GW, Crider JY, Sharif NA. FP prostaglandin receptors mediating inositol phosphates generation and calcium mobilization in Swiss 3T3 Cells: A pharmacological study. J. Pharmacology & Experimental Therapeutics 281: 845-854 (1997).
  97. Yanni JM, Miller ST, Gamache DA, Spellman JM, Xu SX, Sharif NA. A comparison of topical ocular anti-allergy drugs: effects on human conjunctival mast cell mediator release. Annals Allergy, Asthma & Immunology 79: 541-545 (1997).
  98. Crider JY, Xu SX, Griffin BW, Sharif NA. Use of a semi-automated, robotic radioimmunoassay to measure cAMP generated by activation of DP-, EP2- and IP-prostaglandin receptors in human ocular and other cell-types. Prostaglandins, Leukotrienes & Essential Fatty Acids 59: 77-82 (1998).
  99. Sharif NA, Williams GW, Xu SX, Crider JY, Griffin BW, Davis TL. Pharmacological analysis of [3H]PGE1/ [3H]PGE2 and [3H]PGF2α binding in bovine corpus luteum: identification of EP3 and FP prostaglandin receptors and correlation with functional data. J. Pharmacology & Experimental Therapeutics 286: 1094-1102 (1998).
  100. Crider JY, Griffin BW, Sharif NA. Prostaglandin-stimulated adenylyl cyclase activity via a pharmacologically-defined EP2 receptor in human NPE cells. J. Ocular Pharmacology & Therapeutics 14: 293-304 (1998).
  101. Wiernas TK, Davis TL, Griffin BW, Sharif NA. Effects of bradykinin on signal transduction, cell proliferation, and cytokine, prostaglandin E2 and collagenase-1 release from human corneal epithelial cells. British J. Pharmacology 123: 1127-1137 (1998).
  102. Griffin BW, Magnino P, Pang I-H, Sharif NA. Pharmacological characterization of an FP prostaglandin receptor on rat vascular smooth muscle cells (A7r5) coupled to phosphoinositide turnover and intracellular calcium mobilization. J. Pharmacology & Experimental Therapeutics 286: 411-418 (1998).
  103. Sharif NA, Wiernas TK, Griffin BW, Davis TL. Pharmacology of [3H]-pyrilamine binding and the histamine-induced phosphoinositide turnover, Ca2+-mobilization and cytokine release from human corneal epithelial cells. British J. Pharmacology 125: 1336-1344 (1998).
  104. Sharif NA, Wiernas TK, Howe, WL, Griffin, BW, Offord, EA, Pfeifer, AMA. Human corneal epithelial cell functional responses to inflammatory agents and their antagonists. Investigative Ophthalmology & Visual Science 39: 2562-2571 (1998).
  105. Sharif NA, Xu SX. Pharmacological characterization of [3H]-ifenprodil binding to polyamine binding sites on rabbit and rat retinal homogenates: role in neuroprotection? J. Ocular Pharmacol. Therapeutics 15: 271-281 (1999).
  106. Offord E, Sharif NA, Mace K, Tromvoukis Y, Spillare Avanti O E, Howe WL, Pfeifer AMA. Immortalized human corneal epithelial cells for ocular toxicity and inflammation studies. Investigative Ophthalmology & Visual Science 40: 1091-1101 (1999).
  107. Sharif NA, Xu SX. Human retina contains polyamine-sensitive [3H]-ifenprodil binding sites: implications for neuroprotection? British J. Ophthalmology 83: 236-240 (1999).
  108. Yanni JM, Sharif NA, Gamache DA, Miller ST, Weimer LK, Spellman JM. A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs. Acta. Ophthalmologica Scandinavia 77: 33-37 (1999).
  109. Sharif NA, Davis TL, Williams GW. [3H]AL-5848 (9- β -[+]fluprostenol): carboxylic acid of Travoprost (AL-6221), a novel FP-prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. J. Pharmacy & Pharmacology 51: 685-594 (1999).
  110. Crider JY, Griffin BW, Sharif NA. Prostaglandin DP receptors positively coupled to adenylyl cyclase in embryonic bovine tracheal (EbTr) cells: pharmacological characterization. British J. Pharmacology 127: 204-210 (1999).
  111. Davis TL, Sharif NA. Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphor-imaging technology. J. Ocular Pharmacology & Therapeutics 15: 323-336 (1999).
  112. Yanni JM, Weimer L, Sharif NA, Xu SX, Gamache D, Spellman J. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Archives Ophthalmology 117: 643-647 (1999).
  113. Griffin BW, Klimko P, Crider JY, Sharif NA. AL-8810: a novel PGF2α analog with selective antagonist effects at the FP prostaglandin receptor. J. Pharmacology & Experimental Therapeutics 290: 1278-1284 (1999).
  114. Ohia SE, Opere CA, Awe SO, Adams L, Sharif NA. Human, bovine and rabbit retinal glutamate-induced [3H]D-aspartate release: role in excitotoxicity. Neurochemical Research 25: 853-860 (2000).
  115. Sharif NA, Crider JY, Xu SX, Williams GW. Affinities, selectivities, potencies and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids. J. Pharmacology & Experimental Therapeutics 293: 321-328 (2000).
  116. Davis TL, Sharif NA. Pharmacological characterization of [3H]-prostaglandin E2 binding to the cloned human EP4 prostanoid receptor. British J. Pharmacology 130: 1919-1926 (2000).
  117. Sharif NA, Crider JY, Davis TL. AL-3138 antagonizes FP prostanoid receptor-mediated inositol phosphates generation: comparison with some purported FP antagonists. J. Pharmacy & Pharmacology 52: 1529-1539 (2000).
  118. Klimko PG, Griffin BG, Davis TL, Sharif NA. Synthesis and biological activity of a novel 11α-homo-(cyclohexyl)-prostaglandin. J. Medicinal Chemistry 43: 3400-3407 (2000).
  119. Thomas D, Papadopoulo O, Doshi R, Kapin MA, Sharif NA. Retinal ATP and phosphorus metabolites: reduction by hypoxia and recovery with MK-801 and diltiazem. Medical Science Research 28: 87-91 (2000).
  120. Sharif NA, Williams GW, Davis TL. Pharmacology and autoradiography of human DP prostanoid receptors using [3H]-BWA868C, a DP receptor-selective antagonist radioligand. British J. Pharmacology 131: 1025-1038 (2000).
  121. Crider JY, Griffin BW, Sharif NA. Endogenous EP4 prostaglandin receptors coupled positively to adenylyl cyclase in Chinese hamster ovary cells: pharmacological characterization. Prostaglandins Leukotrienes & Fatty Acids 62: 21-26 (2000).
  122. Hellberg MR, Sallee V, McLaughlin M, Sharif NA, DeSantis L, Dean TR, Zinke PW. Preclinical efficacy of Travoprost (Travatan®), a potent and selective FP prostaglandin receptor agonist. J. Ocular Pharmacology & Therapeutics 17: 421-432 (2001).
  123. Harris LC, Awe SO, Opere CA, LeDay AM, Ohia SE, Sharif NA. [3H]-Serotonin release from bovine iris-ciliary body: pharmacology of pre-junctional serotonin (5HT7) auto-receptors. Experimental Eye Research 73: 59-67 (2001).
  124. Crider JY, Sharif NA. Functional pharmacological evidence for EP2 and EP4 prostanoid receptors in immortalized human trabecular meshwork and N-PCE cells. J. Ocular Pharmacology & Therapeutics 17: 35-46 (2001).
  125. Sharif NA, Williams GW, Kelly CR. Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur. J. Pharmacology 432: 211-213 (2001).
  126. Sharif NA, Xu SX, Crider JY, McLaughlin M, Davis TL. Levobetaxolol (Betaxon™) and other β–adrenergic antagonists: preclinical pharmacology, IOP-lowering activity and sites of action in human eyes. J. Ocular Pharmacology & Therapeutics 17: 305-317 (2001).
  127. Crider JY, Xu SX, Sharif NA. Pharmacology of functional endogenous IP prostanoid receptors in NCB-20 cells: comparison with binding data from human platelets. Prostaglandins, Leukotrienes & Essential Fatty Acids 65: 253-258 (2001).
  128. Ohia SE, Awe SO, Opere CA, LeDay AM, Harris LC, Sharif NA. Hypoxia-induced [3H]-D-aspartate release from isolated bovine retina: modulation by calcium channel blockers and glutamatergic agonists and antagonists. Current Eye Research 23: 386-392 (2001).
  129. Sharif NA, Crider JY, Xu SX, McLaughlin M, Davis TL. Levobetaxolol (Betaxon™): In vitro pharmacology, intraocular pressure lowering activity and autoradiographic localization of β–receptors in human eyes. Proc. Western Pharmacology Society 44: 65-68 (2001).
  130. Rangisetty J, Dukat M, Dowd C, Herrick-Davis K, DuPre A, Gadepalli S, Teitler M, Kelly C, Sharif NA, Glennon R. 1-[2-methoxy-5-(3-phenylpropyl)]-2-aminopropane unexpectedly shows 5HT2A serotonin receptor affinity and antagonist character. J. Medicinal Chemistry 44: 3283-3291 (2001).
  131. Sharif NA, Senchyna M, Xu SX. Pharmacological and molecular biological (RT-PCR) characterization of functional TP prostanoid receptors in immortalized human non-pigmented ciliary epithelial cells. J. Ocular Pharmacology & Therapeutics 18: 141-162 (2002).
  132. Sharif NA, Davis, TL. Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J. Pharmacy & Pharmacology 54: 539-547 (2002).
  133. Harris LC, Awe SO, Opere CA, LeDay AM., Ohia SE, Sharif NA. Pharmacology of serotonin receptors modulating electrically induced [3H]norepinephrine release from isolated mammalian iris-ciliary bodies. J. Ocular Pharmacology & Therapeutics 18: 339-348 (2002).
  134. Sharif NA, Kelly CR, Crider JY. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J. Ocular Pharmacology & Therapeutics 18: 313-324 (2002).
  135. Hellberg MR, Conrow R. Sharif NA. McLaughlin, M., Bishop, J, Crider, JY, et al. 3-Oxa-15-cyclohexyl prostaglandin DP receptor agonists as topical anti-glaucoma agents. Bioorganic & Medicinal Chemistry 10: 2031-2049 (2002).
  136. Crider JY, Sharif NA. Adenylyl cyclase activity mediated by β2-adrenoceptors in immortalized human trabecular meshwork and non-pigmented ciliary epithelial cells. J. Ocular Pharmacology & Therapeutics 18: 221-230 (2002).
  137. Hellberg MR, McLaughlin MA, Sharif NA, DeSantis L, Dean TR, Kyba EP, Bishop JE, Klimko PG, Zinke, PW, Selliah RD, Barnes G, DeFaller J, Kothe A, Landry TL, Sullivan EK, Andrew R, Davis AA, Silver L, Bergamini MVW, Robertson S, Weiner AL, Sallee VL. Identification and characterization of the ocular hypotensive efficacy of Travoprost (Travatan® ), a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Survey of Ophthalmology (Suppl #1), 47: S13-S33 (2002).
  138. Sharif NA, Kelly CR, Williams GW. Bimatoprost (Lumigan®) is an agonist at the cloned human ocular FP receptor: real-time FLIPR-based intracellular Ca2+ mobilization studies. Prostaglandins. Leukotrienes. Essent. Fatty Acids. 68: 27-33 (2003).
  139. Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest. Ophthalmology & Visual Science 44: 715-721 (2003).
  140. Kelly CR, Williams GW, Sharif NA. Real-time intracellular Ca2+-mobilization by travoprost acid, bimatoprost, unoprostone and other analogs via endogenous mouse, rat and cloned human FP prostaglandin receptors. J. Pharmacology & Experimental Therapeutics 304: 238-245 (2003).
  141. Sharif NA, Crider JY, Husain S, Kaddour-Djebbar I, Ansari HR, Abdel-Latif AA. Human ciliary muscle responses to FP-class prostaglandin analogs: phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation. J. Ocular Pharmacology & Therapeutics 19: 437-455 (2003).
  142. May JM, Chen H-H, Rusinko A, Lynch, VM, Sharif NA, McLaughlin MA. A novel and selective 5HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano-[3,2-e]indole. J. Medicinal Chemsitry 46: 4188-4195 (2003).
  143. Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J. Ocular Pharmacology & Therapeutics 19: 501-515 (2003).
  144. May JM, McLaughlin MA, Sharif NA, Hellberg MR, Dean TR. Evaluation of the ocular hypotensive response of serotonin 5HT1A and 5HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys. J. Pharmacology & Experimental Therapeutics 306: 301-309 (2003).
  145. Ohia SE, Awe SO, Opere CA, LeDay AM, Harris LC, Kulkarni K, Sharif NA. Glucose deprivation-induced [3H]-D-aspartate release from isolated bovine and human retinae. J. Ocular Pharmacology & Therapeutics 19: 599-609 (2003).
  146. Crider JY, Williams GW, Drace CD, Katoli P, Senchyna M, Sharif NA. Pharmacological characterization of a serotonin receptor (5HT7) stimulating cAMP production in human corneal epithelial cells. Invest. Ophthalmology & Visual Science 44: 4837-4844 (2003).
  147. Selliah RD, Hellberg MR, Sharif NA, McLaughlin MA, Williams GW, Scott DA, Earnest D. Haggard KS, Dean DW, Delgado P, Gaines, MS, Conrow RE, Klimko PG. AL-12182, a novel 11-oxa prostaglandin analog with topical ocular hypotensive activity in the monkey. Biorganic Medicinal Chemistry Letters 14: 4525-4528 (2004).
  148. Sharif NA, Xu SX. Pharmacological characterization and identification of EP3 prostanoid receptor binding sites in hamster uterus homogenates. J. Pharmacy & Pharmacology 56: 197-203 (2004).
  149. Sharif NA, Xu SX. Binding affinities of ocular hypotensive β-blockers levobetaxolol, levobunolol and timolol at endogenous guinea pig β-adrenoceptors. J. Ocular Pharmacology & Therapeutics 20: 93-99 (2004).
  150. Klimko P, Hellberg MR, McLaughlin MA, Sharif NA, Severns B, Williams GW, Haggard KS, Liao J. 15-Fluoro prostaglandin FP agonists: a new class of topical ocular hypotensives. Biorganic Medicinal Chemistry 12: 3451-3469 (2004).
  151. Sharif NA, Williams GW, Crider JY, Xu SX, Davis TL. Molecular pharmacology of the ocular hypotensive DP/EP2 class prostaglandin AL-6598 and localization of DP and EP2 receptor sites in human eyes. J. Ocular Pharmacology & Therapeutics 20: 489-508 (2004).
  152. Sharif NA, Drace CD, Williams GW, Crider JY. Cloned human 5HT1A receptor pharmacology determined using agonist binding and measurement of cAMP accumulation. J. Pharmacy & Pharmacology 56: 1267-1274 (2004)
  153. Glennon RA, Bondarev ML, Khoran N, Young R, May JA, Hellberg MR, McLaughlin MA, Sharif NA. β-Oxygenated analogues of the 5HT2A serotonin receptor agonist 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane. J. Medicinal Chemistry 47: 6034-6041 (2004).
  154. Sharif NA, Davis TL, Williams GW. Ocular hypotensive DP-class prostaglandin receptor affinities determined by quantitative autoradiography on human eye sections. J. Ocular Pharmacology & Therapeutics 21: 121-132 (2005).
  155. Patil RV, Sharif NA. Aquaporin channel-mediated water flow: drug discovery opportunities for ocular and otic diseases. Current Topics in Pharmacology 9: 97-106 (2005).
  156. Sharif NA, Senchyna M. Serotonin receptor subtype mRNA expression in human ocular tissues determined by RT-PCR. Molecular Vision 12: 1040-1047 (2006).
  157. Sharif NA, McLaughlin MA, Kelly CR, Xu SX, Crider JY, Parker J. Preclinical pharmacology of AL-12182, a new ocular hypotensive 11-oxa-prostaglandin analog. J. Ocular Pharmacology & Therapeutics 22: 291-309 (2006).
  158. May JA, Dantanarayana AP, Zinke PW, McLaughlin MA, Sharif NA. 1-((S)-2-Aminopropyl)-1H-indazol-6-ol: (AL-34662) A potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J. Medicinal Chemistry 49: 318-328 (2006).
  159. Sharif NA, Crider JY, Kelly CR, Davis TL. Serotonin-2 (5HT2) receptor-mediated signal transduction in human ciliary muscle cells: role in ocular hypotension. J. Ocular Pharmacology & Therapeutics 22: 389-401 (2006).
  160. Kelly CR, Sharif NA. Pharmacological evidence for a functional serotonin-2B receptor subtype in a human uterine smooth muscle cell line. J. Pharmacology & Expt. Therapeutics 317: 1254-1261 (2006).
  161. Sharif NA, Kelly, CR, McLaughlin MA. Human trabecular meshwork cells express functional serotonin-2 (5HT2) receptors: role in IOP reduction. Investigative Ophthalmology & Visual Science. 47: 4001-4010 (2006).
  162. Sharif NA, Klimko PG. CNS: Ophthalmic Agents, in Comprehensive Medicinal Chemistry II., Vol. 6, Chapter 12, p. 297-320 (Eds: J.B. Taylor & D.J. Triggle), Elsevier, Oxford (2007).
  163. Feng Z, Mohapatra S, Klimko PG, Hellberg M, May JA, Kelly CR, Williams GW, McLaughlin MA, Sharif NA. Novel benzodifuran analogs as potent 5HT2A receptor agonists with ocular hypotensive activity. Bioorganic Medicinal Chemistry Letters 17: 2998-3002 (2007).
  164. Sharif NA, McLaughlin MA, Kelly CR. AL-34662: a potent, selective, and efficacious ocular hypotensive serotonin-2 receptor agonist. J. Ocular Pharmacology & Therapeutics 23: 1-13 (2007).
  165. Sharif NA. Synthetic FP-class prostaglandin-induced contraction of rat uterus smooth muscle in vitro. Prostaglandins Leukotrienes & Essential Fatty Acids 78: 199-207 (2008).
  166. Camras CB, Sharif NA, Wax MB, Stjernshantz J. Bimatoprost, the prodrug of a prostaglandin analogue. British J. Ophthalmology 92: 862-863 (2008).
  167. Sharif NA, Kaddour-Djebbar I, Abdel-Latif AA. Cat iris sphincter smooth muscle contraction: comparison of FP-class prostaglandin analog agonist activities. J. Ocular Pharmacology & Therapeutics 24: 152-163 (2008).
  168. Sharif NA, Klimko P. Update and commentary on the prodrug bimatoprost and a putative prostamide receptor. Expert Review Ophthalmology 4: 477-489 (2009).
  169. Dismuke WM, Sharif NA, Ellis DZ. Human trabecular meshwork cell volume decrease by NO-independent soluble guanylate cyclase activators YC-1 and BAY-58-2667 involves the BKCa ion channel. Invest. Ophthalmology & Visual Science 50: 3353-3359 (2009).
  170. Sharif NA, McLaughlin MA, Kelly CR, Katoli P, Drace C, Husain S, Crosson C, Toris C, Zhan G-L, Camras C. Cabergoline: pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in cynomolgus monkey eyes. Experimental Eye Research 88: 386-397 (2009).
  171. Feng Z, Hellberg MR, Sharif NA, McLaughlin MA, Williams GW, Scott D, Wallace T. Discovery of 13-oxa prostaglandin analogs as novel antiglaucoma agents: synthesis and biological activity. Bioorganic Medicinal Chemistry 17: 576-584 (2009).
  172. Sharif NA, Hellberg PE, Pang I-H, Gamache DA, Yanni JM. Human conjunctival epithelial cell responses to platelet-activating factor: signal transduction and release of pro-inflammatory cytokines. Molecular Vision 15: 1153-1161 (2009).
  173. May JA, Sharif NA, Chen H-H, Liao JC, Kelly CR, Glennon RA, Young R, Li J-X, Rice KC, France CP. Pharmacological properties and discriminative stimulus effects of a novel and selective 5HT2 receptor agonist, AL-38022A [(S)-2-(8,9-dihydro-7H-pyrano[2,3g]indazol-1-yl)-1-methylethylamine]. Pharmacology, Biochemistry & Behavior 91: 307-314 (2009).
  174. Sharif NA. Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular mechanisms of action: novel drug targets for glaucoma treatment. Current Drug Targets 11: 978-993 (2010).
  175. Dismuke WM, Sharif NA, Ellis DZ. Endogenous regulation of human Schlemm’s canal cell volume by nitric oxide signaling. Invest. Ophthalmology & Visual Science 51: 5817-5824 (2010).
  176. Katoli P, Sharif NA, Sule A, Dimitrijevich SD. NPR-B natriuretic peptide receptors in human corneal epithelium: mRNA, immunohistochemical, protein and biochemical pharmacology studies. Molecular Vision 16: 1241-1252 (2010).
  177. Sharif NA, Wiernas TK. Platelet-activating factor (PAF)-induced intracellular signaling and release of cytokines and prostaglandin E2 in immortalized human corneal epithelial cells. J. Ocular Pharmacology & Therapeutics 26: 21-29 (2010).
  178. Faulkner R, Sharif NA, Orr S, Craven R, Moster M, Sall K, Whitson J, Bethem R, Curtis M, Dahlin D. Aqueous humor concentrations of bimatoprost free acid, bimatoprost and travoprost free acid in cataract surgical patients administered multiple topical ocular doses of LUMIGAN® or TRAVATAN®. J. Ocular Pharmacology & Therapeutics 26: 147-156 (2010).
  179. Henderson AJ, Hadden M, Guo C, Douglas N, Decornez H, Hellberg MR, Rusinko A, McLaughlin M, Sharif NA, Drace C, Patil R. 2,3-Diaminopyrines as rho kinase inhibitors. Bioorganic Medicinal Chemistry Letters 20: 1137-1140 (2010).
  180. Dibas A, Oku H, Fukuhara M, Kurimoto T, Ikeda T, Patil RV, Sharif NA, Yorio T. Changes in ocular aquaporins expression following optic nerve crush. Molecular Vision 16: 330-340 (2010).
  181. Ramachandran C, Patil RV, Sharif NA, Srinivas SP. Effect of elevated intracellular cAMP on actomyosin contraction in bovine trabecular meshwork cells. Investigative Ophthalmology & Visual Science 52: 1474-1485 (2011).
  182. Sharif NA, May JA. Potential for serotonergic agents to treat elevated intraocular pressure and glaucoma: focus on 5HT2 receptor agonists. Expert Reviews Ophthalmology 6: 105-120 (2011).
  183. Sharif NA, Crider JY. Human choroidal melanocytes signal transduction responses to various pharmacological agents: focus on endothelin. Current Eye Research 36: 462-468 (2011).
  184. Sharif NA. Ocular hypotension: involvement of serotonergic 5HT2 receptors. Chapter 26, in: The pathophysiology of central 5HT2C receptors”. (Di Giovanni, G, Esposito, E & Di Matteo, V, Eds), Humana Press, Springer Publishing Company, New York, NY. (2011).
  185. Sharif NA, Crider JY. Intracellular signaling in human iridial fibroblasts and iridial melanocytes in response to prostaglandins, endothelin, isoproterenol and other pharmacological agents. Current Eye Research 36: 310-320 (2011).
  186. Ramachandran C, Patil RV, Combrink K, Sharif NA, Srinivas SP. Rho-Rho kinase pathway in the actomyosin contraction and cell-matrix adhesion in immortalized human trabecular meshwork cells. Molecular Vision 17: 1877-1890 (2011).
  187. Sharif NA, Xu S, Li L, Katoli P, Kelly CR, Wang Y, Cao S, Patil R, Husain S, Klekar L, Scott D. Protein expression, biochemical pharmacology of signal transduction, and relation to IOP modulation by bradykinin B2-receptors in ciliary muscle. Molecular Vision 19: 1356-1370 (2013).
  188. Bhattacharya SK, Lee RK, Grus FH, and the Seventh ARVO/Pfizer Ophthalmics Research Institute Conference Working Group. (Sharif NA, Participant/Observer). Molecular Biomarkers in Glaucoma. Invest. Ophthalmology Visual Science 54: 121-131 (2013).
  189. Sharif NA, Katoli P, Scott D, Li L, Kelly CR, Xu S, Husain S, Toris C, Crosson C. FR-190997, [AL-44205], a non-peptide bradykinin B2-receptor partial agonist, is a potent and efficacious intraocular pressure lowering agent in ocular hypertensive cynomolgus monkeys. Drug Development Research 5: 211-223 (2014).
  190. Sharif NA, Katoli P, Kelly CR, Li L, Xu S, Wang Y, Klekar L, Earnest D, Yacoub S, Hamilton G, Jacobson N, Shepard AR, Ellis D. Trabecular meshwork bradykinin receptors: mRNA levels, immunohistochemical visualization, signaling processes pharmacology and linkage to IOP changes. J. Ocular Pharmacology & Therapeutics 30: 21-34 (2014).
  191. Chen H-H, Namil A, Severns B, Ward J, Kelly CR, Drace C, McLaughlin MA, Yacoub S, Li B, Patil R, Sharif NA, Hellberg MR, Rusinko A, Pang I-H, Combrink KD. In vivo optimization of 2,3-diaminopyrazine Rho kinase inhibitors. Bioorganic Medicinal Chemistry Letters 24: 1875-1879 (2014).
  192. Sharif NA, Wang Y, Katoli P, Xu S, Kelly CR, Li L. Human non-pigmented ciliary epithelium bradykinin B2-receptors: receptor localization, pharmacological characterization of intracellular Ca2+ mobilization, and prostaglandin secretion. Current Eye Research 39: 378-389 (2014).
  193. Sharif NA, Li L, Katoli P, Xu S, Veltman J, Li B, Scott D, Wax M, Gallar J, Acosta C, Belmonte C. Preclinical pharmacology, ocular tolerability and ocular hypotensive efficacy of a novel non-peptide bradykinin mimetic small molecule. Experimental Eye Research 128: 170-180 (2014).
  194. Sharif NA. Novel potential treatment modalities for ocular hypertension: focus on angiotensin and bradykinin system axes. J. Ocular Pharmacology & Therapeutics 31: 131-145 (2015).
  195. May JA, Sharif NA, McLaughlin MA, Chen H-H, Severns BS, Kelly CR, Holt WF, Young R, Glennon RA, Hellberg, MR, Dean TR. Ocular hypotensive response in non-human primates of (R)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol a selective 5-HT2 receptor agonist. J. Medicinal Chemistry 58: 8818-8833 (2015).
  196. Sharif NA, Klekar L, Li L, Xu S. Ocular hypotensive activity of a non-peptide bradykinin B2-receptor antagonist (WIN-64338) in Dutch-Belt rabbits: a case of poly-pharmacology in action. Int. J. Ophthalmology & Clinical Research 2.3 [8 pages] (2015).
  197. Sharif NA, Patil R, Li L, Husain S. Human ciliary muscle cell responses to kinins: activation of ERK1/2 and pro-matrix metalloproteinases secretion. World J. Ophthalmology 6: 20-27 (2016).
  198. Patil R, Xu S, Rusinko A, Feng Z, Katoli P, May JA, Hellberg M, Sharif NA, Wax M, Irigoyen M, Clarke M, Bordeau B, McGraith S, Luche M, van Hoek A, Brittain T, Brown P, Colbert D, Kumari SS, Varadaraj K, Mitra AK, Carr G. Rapid identification of novel inhibitors of aquaporin-1 channel by high-throughput screening. Chemical Biology & Drug Design 87: 794-805 (2016).
  199. Sharif NA. Prospects of treating ocular hypertension and glaucoma with peptidic and non-peptide kinin mimetic drugs. JOJ Ophthalmology 3(1): 555601. DOI 10.19080/JOJO 2017.03.555601 [21 Pages] (2017).
  200. Sharif NA. Ocular hypertension and glaucoma: a review and current perspectives. Int. J. Ophthalmology & Visual Science. 2(3): 22-36 (2017).
  201. Sharif NA, Ohia SE, Yorio T. Introduction to Volume 1 and Volume 2 of JOPT Special Issue titled “Preclinical research on ocular drug/device discovery and development”. J. Ocular Pharmacology Therapeutics 34: 1-3 (2018).
  202. Sharif NA. iDrugs and iDevices discovery and development- preclinical assays, techniques and animal model studies for ocular hypotensives and neuroprotectants. J. Ocular Pharmacology Therapeutics 34: 7-39 (2018).
  203. Sharif NA. Glaucomatous optic neuropathy treatment options: the promise of novel therapeutics, techniques and tools to help preserve vision. Neural Regeneration Research 13: 1145-1150 (2018).
  204. Patil RV, Wang H, Sharif NA, Mitra A. Aquaporins: novel targets for age-related ocular disorders. J. Ocular Pharmacology & Therapeutics 177-197 (2018).
  205. Ohia SE, Njie-Mbye YF, Robinson J, Mitchell L, Mckoy M, Opere CA, Sharif NA. Serotonin-2B/2C receptors-mediate bovine ciliary muscle contraction: role in IOP regulation. J. Ocular Pharmacology Therapeutics 34: 70-75 (2018).
  206. Njie-Mbye YF, Robinson J, Mitchell L, Mckoy M, Opere CA, Ohia SE, Sharif NA. Pharmacology of serotonin receptors causing contraction of bovine isolated posterior ciliary arteries: role in ocular blood-flow modulation. J. Ocular Pharmacology Therapeutics 34: 134-140 (2018).
  207. Opere CA, Heruye S, Njie-Mbye YF, Ohia SE, Sharif NA. Regulation of excitatory amino acid transmission in the retina: studies on neuroprotection. J. Ocular Pharmacology Therapeutics 34: 107-118 (2018).
  208. Klimko P, Sharif NA. Discovery, characterization and clinical utility of prostaglandin agonists for treatment of glaucoma. British J Pharmacology 176: 1051-1058 (2019).
  209. Sharif NA, Klimko P. Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility. British J Pharmacology 176: 1059-1078 (2019).
  210. Sharif NA. Discovery to launch of anti-allergy (Emadine; Patanol/Pataday/Pazeo) and anti-glaucoma (Travatan; Simbrinza) ocular drugs, and generation of novel pharmacological tools such as AL-8810. ACS Pharmacology & Translational Science 3: 1391-1421 (2020).
  211. Sharif NA. Pharmacodynamic Evaluation: Ocular Pharmacology, in “Drug Discovery and Evaluation: Methods in Clinical Pharmacology” (Franz J. Hock and Michael R. Gralinski, Eds). Chapter 54, 46 pages, Springer Publishing Company ( (2020).
  212. Sharif NA. Research, discovery and development of novel therapeutics for eye diseases allergic conjunctivitis and glaucoma. J Ophthalmic Studies 2(2): (2020).
  213. Sharif NA. Inflammatory and immunological aspects of glaucoma, optic neuritis and neuromyelitis optica impacting eyesight. In Vol 7: Translational Neuroimmunology (Nima Rezaei, Ed), Elsevier Science Publishers (in press, 2021).
  214. Gunawan M, Low CB, Neo K, Yeo SW, Ho C, Veluchamy A, Chan A, Sharif NA, Kageyama M. The role of autophagy in chemical proteasome inhibition model of retina degeneration. Int. J. Molecular Sciences 22(14): 7271 (2021).
  215. Sharif NA. Therapeutic drugs and devices for tackling ocular hypertension and glaucoma, and need for neuroprotection and cytoprotective therapies. Frontiers in Pharmacology 12: 729249 (2021). doi: 10.3389/fphar.2021. 729249 (46 pages) (2021).
  216. Choudry N, Sharif NA. Current research perspectives on pharmacological and non-pharmacological treatment options for myopia. J. Ocular Pharmacology Therapeutics (submitted, 2021).
  217. Levin LA, Patrick C, Choudry NB, Sharif NA, Goldberg JL. Neuroprotection in neurodegenerations of the eye and brain: lessons from the past and directions for the future. Progress in Retinal &Eye Research (submitted).
  218. Sharif NA. Targeting of signal transduction pathway components to mitigate selected ocular disorders. Acta Scientific Ophthalmology (2021, submitted).